

Declaration of Interests for ENCePP Studies

INTRODUCTION

This document includes your personal details and your declaration of interests to be made public in line with the provisions of the ENCePP Code of Conduct. All parts must be duly completed. Your declaration will not be accepted if any fields are left empty. You are responsible for the accuracy and completeness of the submitted information.

The form is designed to be filled in electronically and emailed as PDF to the ENCePP Secretariat for publication on the ENCePP E-Register of Studies. In addition, a printed and hand signed copy has to be returned to the ENCePP Secretariat.

SECTION 1: PERSONAL DETAILS

First Name:	Blin
Last Name:	Patrick
Organisation / Research Centre :	Pharmacology department Bordeaux Segalen University / INSERM CICP 005
Country:	France
Contact e-mail Address:	patrick.blin@pharmaco.u-bordeaux2.fr
Drug usage pat	terns of Pylera in France using the National Claims Database
ENCePP Study Reference Nur	nber: ENCEPP/SDPP/ 3 9 0 1
Are you the (Primary) Lead Ir	nvestigator of the above study? No 🗌 Yes 🗸
Are you an investigator/resea	rcher contributing to the above study No 🗸 Yes

SECTION 2: DECLARATION	OF INTERESTS RE	LAT	ED :	го Р	HARM	ACE	UTIC	AL IN	DUSTR	Y
In this section you must declare any i past 3 years. If you have interests to be answered.										
2.1 Employment		No	\bigcirc	Yes	0					
Employment in a pharmaceutic Pharmaceutical company includes sup and maintenance of a medicinal produ pharmaceutical company.	ply or service companie	s whi	ch cc	ntrib	ute to res	earch	i, deve	lopmer	nt, product you by a	ion
2.2 Financial Interest		No	Ø	Yes	0					
Financial interests in the capit. Financial interests relate to current he managed investment funds/pensions	olding of shares of a pha	rmac	eutic	al cor	npany wi					ently
2.3 Patent		No	\bigcirc	Yes	0					
Patent for a medicinal product Relates to a patent for a medicinal pro- centre, and you as individual are the l	oduct currently owned by	y eith	ier yo	ou as	individua	l or y	our orç	ganisat	ion/ resea	rch
2.4 Consultancy		No	0	Yes	②					
Consultancy for a pharmaceuti Consultancy refers to provision of adv including but not limited to reviewing of contractual arrangements or any fo Note that conference/seminar attenda honorarium. Please specify the pharmaceutical company	ice or services to a phar activities, data monitoria rm of remuneration sucl ince is not considered a	mace ng, si h as c consi	eutica tatist consu ultan	ol comical authors Iting Cy but	npany exc nalysis, e fees or h t should b	cludin nd po onora oe ino	g the coint cor aria. licated	oncern mmitte	ed study a es, regard	less
Period:	Past									
From Month: 01 From Year: 20	08									
Name of Pharmaceutical Company:	BMS						,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
Type of consultancy:	Methodology and scienti	ific B	oard					\exists		
Please specify the pharmaceutical company	y, types of consultancy and	date	s whe	n fees	/honoraria	paid:				
Period: Current C	Past									
From Month: 09 From Year: 2	Oイフ To Month	:	12		To Year:	2	101	2		
Name of Pharmaceutical Company:	Roche				\$==\$======					
Type of consultancy:	Scientific board									
2.5 Strategic Advisory Role		No	⊘	Yes	0					
Strategic Advisory role on active study application? Participation with the right to vote one				_						the

Participation with the right to vote on/influence the output in a (scientific) advisory board/steering committee with the role of providing advice/expressing opinions on the future strategy, direction or development activities of a pharmaceutical company either in terms of general or product-related strategy, regardless of contractual arrangements or any form of remuneration.

2.6 Grant / Funding	No ○ Yes �	

Grant/funding from a pharmaceutical company other than funds contemplated in the concerned study contract?

Refers to a grant or funding from a pharmaceutical company which is currently being received by your research group, irrespective of whether you are employed or a volunteer, and you receive no personal gain.

Please specify the pharmaceutical company:

Name of Pharmaceutical Company	Comments	
Aptalis		
Astra Zeneca		
BMS		
GSK		
Helsinn		
Lundbeck		
Novartis		
Pfizer		
Pierre Fabre		
Sanofi		
Takeda		
UCB Pharma		

_	ATTA			BIN/ A		of N I also has he	
SE	CILU	IN :	5: A	NYU	HEK	INTER	CESIS

No 🕢	Yes (
140 (4)	103

In this section you should declare any other interests to be made known to the public.

Any other relationships/conditions/circumstances that present a potential conflict of interest, including matters relating to members of your family?

Further to the interests declared above, I do hereby declare on my honour that I do not have any further interests or facts that should be made public in relation to the conduct of the study.

Should there be any change of the above due to the fact that I acquire additional interests, I shall promptly notify the ENCePP Secretariat and complete a new Declaration of Interests detailing the changes.

I confirm the information declared on this form is accurate to the best of my knowledge and I consent to my information being stored electronically and published on the ENCePP E-Register of Studies.

FULL NAME:	Blin Patrick	Date:	02/08/2013
SIGNATURE:		,	Proceeding States (sp. pr

Send signed copy to **ENCePP Secretariat European Medicines Agency** 7 Westferry Circus **Canary Wharf** London, E14 4HB UK